Manufacturing, Cell Therapies

Bayer Acquires BlueRock Therapeutics, Boosts Cell Therapy Stake

August 09, 2019

The acquisition will boost Bayer’s cell-therapy development programs, with an initial focus on neurology, cardiology, and immunology.

PTC Therapeutics Acquires Biologics Facility from Bristol-Myers Squibb

August 09, 2019

The facility will support gene therapy production and continued development of PTC’s pipeline of investigational medicines.

Industrializing Cell and Gene Therapies

August 01, 2019

Now that the first genetically modified cell therapies are being manufactured, the industry must move beyond “whatever works” to meet growing demand.

Bringing Gene Therapies to Market

August 01, 2019

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

Gene Therapy Production Must Pass Regulatory Hurdles

August 01, 2019

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

China Invests in Gene Therapy Research

August 01, 2019

Researchers in China are playing a role in advancing gene therapy development.

Catalent Biologics Announces Long-Term Strategic Agreement to Develop Zolgensma

July 17, 2019

Catalent Biologics has entered into a long-term strategic agreement to develop and manufacture an AveXis gene therapy treatment for spinal muscular atrophy (SMA), Zolgensma.

Kite Announces New Facility for Viral Vector Production

July 16, 2019

Kite, a Gilead company, announced plans to build a new facility for the development and manufacturing of the starting material for the production of cell therapies, viral vectors.

Amicus Therapeutics Enters Strategic Manufacturing Collaboration with Thermo

July 02, 2019

Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.

Catalent Biologics Acquires Vaccine Manufacturing Facilities

July 01, 2019

Novavax will sell two Maryland-based vaccine development and manufacturing facilities for Catalent’s expanding gene therapy footprint.